You searched for "RVO"
The incidence of retinal vein occlusion in patients with pseudoexfoliation glaucoma
In this retrospective study the authors aimed to evaluate PXF as an independent risk factor for the occurrence of retinal vein occlusion (RVO). Three hundred PXF glaucoma patients (PXF group), 300 non-PXF glaucoma patients, and 599 non glaucoma non-PXF (nGnP...
OCTA FAZ measurements in vein occlusion
Previous studies have confirmed that foveal avascular zone (FAZ) enlargement is correlated with visual acuity impairment in patients with retinal vein occlusion (RVO). This current study aimed to evaluate the OCT angiography parameters: the area of FAZ, foveal and parafoveal...
Thrombophilia in patients with retinal vein occlusion
The authors present a retrospective study of the prevalence of thrombophilia in patients with retinal vein occlusion. The study cohort included 88 patients with central retinal vein occlusion (CRVO), 51 patients with branch retinal vein occlusion (BRVO) and 40 controls....
OCT angiography and retinal vein occlusions
In this retrospective, observational case series, the authors set out to evaluate the morphology of the superficial and deep capillary plexa of eyes that suffered a retinal vein occlusion (RVO) on OCT angiography (OCTA) and compare the findings with fluorescein...The management of retinal vein occlusions: a summary
Retinal vein occlusions (RVO) are the most common cause of visual loss from retinal vascular disease second to diabetic retinopathy. Vision is lost due to ischaemia, macular oedema and / or haemorrhage which ultimately effects a patient’s quality of life...
Does Ozurdex affect perfusion status in vein occlusion?
Ozurdex (intravitreal dexamethasone implant) has been approved by National Institute of Health & Care Excellence (NICE) for treatment of patients with macular oedema associated with vein occlusion. This study looks at the change in peripheral perfusion status in patients with...
Rebound phenomenon after IVT triamcinolone acetonide for macular oedema
In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...A case of ‘60-day glaucoma’
Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...
Systemic pharmacology of intravitreal anti-VEGF
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Evaluation of Optive® in ocular discomfort after anti-VEGF intravitreal injection
In this study the authors prospectively evaluated the efficacy of Optive® eye drops after in full, then abbreviation - intravitreal injection (IVT). Patients naïve to IVT were included in the study. No artificial tear treatment was prescribed after the first...
